Clinical role of fluoroquinolones in patients with respiratory tract infections

Infectious Diseases in Clinical Practice

Volumn 8, Issue 4 SUPPL. 1, 1999, Pages

  Quintiliani, Richard ^a,b   Owens Jr , Robert C ^c,d   Grant, Edward M ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c MAINE MEDICAL CENTER   (United States)

^d UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AZITHROMYCIN; CEFEPIME; CEFOTAXIME; CINOXACIN; CIPROFLOXACIN; ENOXACIN; ERYTHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MEROPENEM; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; OXOLINIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TAZOBACTAM; TROVAFLOXACIN;

AREA UNDER THE CURVE; DRUG COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW;

EID: 0032960646     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199905001-00006     Document Type: Review

References (42)

1. Pechire JC, Gootz TD. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Eur J Clin Microbiol Infect Dis 1998;17:405-12.
2. Tankovic J, Perichon B, Dural J, et al. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother 1996;40:2505-10.
3. Perez-Trallero E, Garcia-Arenzana JM, Jimenez JA, et al. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumoniae treated with ciprofloxacin. Eur J Clin Microbiol Infect Dis 1990; 9:903-6.
4. Vogelman B, Gudmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-47.
5. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
6. Craig W. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur J Clin Microbiol Infect Dis 1993;(Suppl 1):6-8.
7. Dudley MN. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to fluoroquinolones. Am J Med 1991;9(Suppl 6A):45S-50S.
8. Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483-90.
9. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-9.
10. Preston SL, Drusano GL, Beramn AL, et al. Prospective development of pharmacodynamic relationships between measures of levofloxacin exposure and measures of patient outcome [abstract]. Abstracts of the 36th Interscience Conference of Antimicrobial Agents and Chemotherapy; New Orleans (LA); 1992. p. 49.
11. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles. I. Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP 1991;25:1050-7.
12. Lee BL, Padula AM, Kimbrough RC, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991;325:520-1.
13. Gordon JJ, Kaufman CA. Superinfection with streptococcus pneumoniae during therapy with ciprofloxacin. Am J Med 1990;89:383-4.
14. Righter J. Pneumonococcal meningitis during intravenous ciprofloxacin therapy [comment]. Am J Med 1990; 88:538.
15. Quintiliani R, Nicolau DP, Nightingale CH. Pharmacokinetic and pharmacodynamic principles in antibiotic usage. In: Yu V, Ballow, editors. Infectious diseases and antimicrobial therapy of the ears, nose and throat. Philadelphia: W.B. Sanders Co.; 1997. p. 48-55.
16. Ebert SC. Pharmacokinetic and pharmacodynamic considerations in antibiotic selection for different pneumonia setting. Infect Dis Clin Pract 1997;6(Suppl 2):543-8.
17. Girard AE, Girard D, Gootz TD, et al. In vivo efficacy of trovafloxacin (CP-99.219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae and Bacteroides fragilis. Antimicrob Agents Chemother 1995;39:2210-6.
18. Bartlett JG, Mundy LM. Community-acquired pneumoniae. N Engl J Med 1995;333:1618-24.
19. Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med 1985;78(Suppl 6B): S45-S51.
20. National Center for Health Statistics. Current estimates from the National Health Interview Survey, United States, 1991. Vital and health statistics [series 10]. Washington (DC): U.S. Government Printing Office; Dec 1992. No. 184.
21. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991;115:428-36.
22. File TM Jr. Etiology and incidence of community-acquired pneumonia: a prospective cohort study. Infect Dis Clin Pract 1996;5(Suppl 4):S127-S135.
23. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcome of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996;275:134-41.
24. File TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of iv/po levofloxacin vs. ceftriaxone/cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72.
25. Bartlett JG, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811-38.
26. Bedos JP, Rieux V, Bauchet J, et al. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains in a mouse pneumonia model. Antimicrob Agents Chemother 1998;42:862-7.
27. Andrews JM, Honeybourne NP, Brenwald D, et al. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fiber-optic bronchoscopy. J Antimicrob Chemother 1997;39:797-802.
28. Garcia de-Lomas J, Millas E, Lazaro A, et al. A comparison study on the efficacy of the new quinolones alatrofloxacin in the treatment of experimental legionellosis in guinea pigs. Eur J Clin Microbiol Infect Dis 1998;17: 420-3.
29. Edelstein PH. Antimicrobial chemotherapy for Legionnaires disease: time for a change. Ann Intern Med 1998;129:328-30.
30. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148: 1418-26.
31. Marrie TJ. Epidemiology of community-acquired pneumonia in the elderly. Semin Respir Infect 1990;5:260-8.
32. Leroy D, Santre C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995;21:23-31.
33. Richerson MA, Ambrose PG, Quintiliani R, et al. Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia. Infect Dis Clin Pract 1998;7:227-33.
34. Griffen JJ, Meduri GU. New approaches to the diagnosis of nosocomial pneumonia. Med Clin North Am 1994; 78:1091-122.
35. Chastre J, Fagon J, Trouillet JL. Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units. Clin Infect Dis 1995;21(Suppl 3):S226-S237.
36. Kaatz GW, Seo SM, Aeschlimann JR, et al. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1998; 42:254-6.
37. Washington JA, Jones RN, Gerlach EH, et al. Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime. Antimicrob Agents Chemother 1993;37:1696-700.
38. Klepser ME, Patel KB, Nicolau DP, et al. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995:2503-10.
39. Quintiliani R, Cooper BW, Briceland LL, et al. Economic impact on streamlining antibiotic administration. Am J Med 1987;82:391-4.
40. Maki DG. Infection due to infusion therapy. In: Bennett JV, Brachman PA, editors. Hospital infections. Boston: Little, Brown; 1986. p. 561-80.
41. Read I, Body GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992;15:197-210.
42. Arnow PM, Quimosing EM, Beach M. Consequences of intravascular catheter sepsis. Clin Infect Dis 1993;16: 778-84.